Key Events This Week
28 Sep: Stock opens week at ₹1,630.70 amid broad market weakness
29 Sep: Venus Remedies hits upper circuit at ₹1,710.90, rating upgraded to Buy
30 Sep: Another upper circuit hit at ₹1,796.40, technical momentum shifts bullish
1 Oct: Slight profit booking, closes at ₹1,784.40 (-0.67%)
28 September 2026: Weak Market Start Amid Sensex Decline
Venus Remedies began the week at ₹1,630.70, down 2.36% from the previous Friday’s close of ₹1,670.10. This decline occurred alongside a broader market sell-off, with the Sensex falling 1.60% to 34,788.97. The stock’s volume was modest at 5,556 shares, reflecting cautious investor sentiment amid negative market conditions. Despite the weak start, Venus Remedies was positioned for a rebound given its technical setup and fundamental strength.
29 September 2026: Upper Circuit Hit and Rating Upgrade Boost Momentum
On 29 September, Venus Remedies surged to hit its upper circuit limit, closing at ₹1,710.90, a 4.92% gain on the day. The stock opened with a gap up of 4.63% and maintained strong buying interest throughout the session. The total traded volume more than doubled to 11,762 shares, signalling robust demand. This price action contrasted sharply with the Sensex’s 0.48% decline to 34,621.52, highlighting the stock’s relative strength.
Crucially, this day also saw MarketsMOJO upgrade Venus Remedies’ Mojo Grade from Hold to Buy, reflecting improved financial quality, valuation, and technical momentum. The company’s net-debt-free status, strong profit growth of 139.27% in the latest quarter, and sustained earnings over seven consecutive quarters underpinned this upgrade. The stock’s price-to-book ratio of 3.4 and low PEG ratio of 0.1 justified the premium valuation amid strong fundamentals.
Strong fundamentals, steady climb upward! This Large Cap from Telecommunication sector earned its Reliable Performer badge through consistent execution. Safety meets solid returns here!
- - Reliable Performer certified
- - Consistent execution proven
- - Large Cap safety pick
30 September 2026: Consecutive Upper Circuit and Technical Bullish Shift
Venus Remedies continued its strong run on 30 September, again hitting the upper circuit limit to close at ₹1,796.40, a 5.00% gain from the previous close. The stock outperformed both its Pharmaceuticals & Biotechnology sector, which declined 0.63%, and the Sensex, which fell marginally by 0.17% to 34,564.37. The total traded volume was 4,146 shares, with delivery volumes surging nearly 93% compared to the five-day average, indicating rising investor conviction.
Technical indicators shifted decisively bullish, with daily moving averages turning positive and monthly MACD signalling strong momentum. Despite a mildly bearish weekly MACD, the overall technical outlook improved, supporting the stock’s upward trajectory. The regulatory freeze triggered by the upper circuit hit reflected unfilled buy orders, a bullish sign of latent demand.
Venus Remedies’ market capitalisation rose to ₹2,288 crore, and the Mojo Score was upgraded to 74.0, reinforcing the Buy rating. The stock’s year-to-date return of 123.06% dwarfed the Sensex’s negative 14.89%, highlighting its exceptional performance within a pressured market environment.
Thinking about Venus Remedies Ltd? Our real-time Verdict report breaks down everything – from financial health and peer comparison to technical signals and fair valuation for this micro-cap stock!
- - Real-time Verdict available
- - Financial health breakdown
- - Fair valuation calculated
1 October 2026: Minor Profit Booking Amid Market Weakness
The week closed on 1 October with Venus Remedies retreating slightly by 0.67% to ₹1,784.40 on increased volume of 10,984 shares. This minor pullback followed two days of strong gains and upper circuit hits, reflecting typical profit booking. The Sensex declined 0.99% to 34,221.41, continuing the broader market weakness. Despite the dip, the stock remained well above its week’s opening price and key moving averages, maintaining a positive technical stance.
| Date | Stock Price | Day Change | Sensex | Day Change |
|---|---|---|---|---|
| 2026-09-28 | ₹1,630.70 | -2.36% | 34,788.97 | -1.60% |
| 2026-09-29 | ₹1,710.90 | +4.92% | 34,621.52 | -0.48% |
| 2026-09-30 | ₹1,796.40 | +5.00% | 34,564.37 | -0.17% |
| 2026-10-01 | ₹1,784.40 | -0.67% | 34,221.41 | -0.99% |
Key Takeaways
Strong Outperformance: Venus Remedies outpaced the Sensex by nearly 10% this week, demonstrating resilience amid a broadly declining market. The stock’s 6.84% weekly gain contrasts with the Sensex’s 3.20% loss, highlighting its relative strength.
Consecutive Upper Circuits: The two consecutive upper circuit hits on 29 and 30 September reflect intense buying interest and unfilled demand, signalling robust investor confidence and technical momentum.
Rating Upgrade and Fundamentals: The upgrade from Hold to Buy by MarketsMOJO was supported by strong financial metrics including net-debt-free status, rapid profit growth, and consistent earnings. The company’s valuation, while premium, is justified by its growth trajectory and market-beating returns.
Technical Momentum Shift: Technical indicators have shifted from mildly bullish to bullish, with daily moving averages and monthly MACD supporting further upside potential. However, some weekly indicators remain mildly bearish, suggesting possible short-term consolidation.
Liquidity and Micro-Cap Status: Despite strong price action, volumes remain moderate, reflecting the stock’s micro-cap classification. Investors should be mindful of potential volatility and liquidity constraints.
Conclusion
Venus Remedies Ltd’s performance over the week ending 1 October 2026 was marked by strong gains, technical upgrades, and a significant rating improvement. The stock’s ability to hit consecutive upper circuits amid a weakening Sensex underscores its robust momentum and investor appeal within the Pharmaceuticals & Biotechnology sector. While minor profit booking was observed on the final trading day, the overall trend remains positive, supported by solid fundamentals and bullish technical signals. Market participants should continue to monitor volume trends and technical indicators for signs of sustained momentum or potential consolidation.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
